ArticleInternational journal of clinical oncology2025
Clinical utility of a novel perioperative quality assessment metric, trifecta, for radical cystectomy.
Article in International journal of clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAssessing the quality of surgical procedures is crucial for improving outcomes in radical cystectomy (RC). While the Pentafecta metric has been used, its reliance on the absence of local recurrence within 1 year delays postoperative assessment. For timely clinical decision-making, a new metric that facilitates earlier evaluation is needed. We propose such a metric, named "Trifecta". We evaluated its impact on prognosis and identified predictors for achieving it.
methodsThe "Trifecta" metric was defined as meeting three criteria: adequate lymphadenectomy (≥ 10 nodes), negative surgical margins, and absence of Clavien-Dindo grade 3-5 complications within 30 days after surgery. This retrospective study analyzed data from patients who underwent RC and lymphadenectomy between April 2014 and June 2024. Kaplan-Meier analysis and Cox proportional hazards models were used to assess oncological outcomes, while logistic regression was used to identify predictors for failing to achieve "Trifecta" .
resultsOf the 196 patients included, 121 (61.7%) achieved "Trifecta" and this was significantly associated with improved intrapelvic RFS (HR 0.42; P = 0.014), CSS (HR 0.56; P = 0.032), and OS (HR 0.57; P = 0.020) but not MFS (HR 0.85; P = 0.620). Low serum levels of albumin were significantly associated with "Trifecta" failure (OR 2.06; P = 0.021), but not with survival outcomes.
conclusionAchieving "Trifecta" was associated with improved survival outcomes, and low serum levels of albumin predicted a higher likelihood of failure to achieve it. The "Trifecta" metric enables early and clinically relevant evaluation of surgical quality, offering a practical alternative to traditional metrics.
Indexed as
Identifiers
40632385What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.